A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Trial Profile

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Haematological malignancies; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Genentech
  • Most Recent Events

    • 27 Jul 2017 Planned End Date changed from 31 May 2018 to 7 May 2018.
    • 27 Jul 2017 Planned primary completion date changed from 30 Sep 2017 to 7 May 2018.
    • 06 Jun 2017 Safety/efficacy and biomarker results in patients with endometrial cancer (n=15), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top